"Corbus Pharmaceuticals' Stock Soars 300% on Positive Phase 1 Cancer Study Results"
Corbus Pharmaceuticals' shares surged over 200% after reporting positive results from its Phase 1 study of CRB-701, a next generation nectin-4 targeting antibody drug conjugate, showing encouraging safety and efficacy in patients with nectin-4 positive tumors. The study is being conducted in China and enrolling participants with metastatic urothelial cancer and other solid tumors confirmed to have nectin-4 positive tumors.